Palvella Therapeutics, Inc. (PVLA) Common Equity (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Common Equity for 12 consecutive years, with -$87.4 million as the latest value for Q3 2024.
- On a quarterly basis, Common Equity fell 386.48% to -$87.4 million in Q3 2024 year-over-year; TTM through Sep 2024 was -$87.4 million, a 386.48% decrease, with the full-year FY2023 number at -$74.5 million, up 20.57% from a year prior.
- Common Equity was -$87.4 million for Q3 2024 at Palvella Therapeutics, down from -$80.8 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $53.9 million in Q3 2021 to a low of -$93.8 million in Q4 2022.
- A 5-year average of $8.8 million and a median of $38.2 million in 2021 define the central range for Common Equity.
- Peak YoY movement for Common Equity: surged 139.53% in 2020, then crashed 597.3% in 2024.
- Palvella Therapeutics' Common Equity stood at $31.0 million in 2020, then soared by 63.58% to $50.8 million in 2021, then plummeted by 284.76% to -$93.8 million in 2022, then increased by 20.57% to -$74.5 million in 2023, then fell by 17.35% to -$87.4 million in 2024.
- Per Business Quant, the three most recent readings for PVLA's Common Equity are -$87.4 million (Q3 2024), -$80.8 million (Q2 2024), and -$76.9 million (Q1 2024).